How Life Sciences Companies Can Create Real Impact With Patient Engagement

For more than 20 years now, companies in the life sciences industry have waved the banner of patient-centricity, spending on advisory boards, listening sessions and even “patient weeks” in their offices.

But if we’re being honest, these activities are often more performative than substantive. Many organizations collect patient stories and survey data but struggle to translate any of it into measurable changes in what they do and how they operate, whether it is designing trials or serving people living with various conditions. Although this type of patient engagement serves as a visible signal of empathy, it often fails to become a core engine of problem‑solving that unlocks value or drives better outcomes.

Based on our combined experience — as patient advocacy leaders and as strategic advisers to the industry — we have created a maturity curve of patient engagement. It defines the key dimensions (for the organization, its capabilities and relationships) and provides tools to elevate activities and achieve meaningful impact, not only on patient lives but also on the bottom line.

As organizations mature in their work with patients, activities move from ad hoc to sustained; the approach shifts from a siloed function to a cross-functional effort; the focus evolves from sponsored events to sustained engagement; relationships progress into partnerships with advocacy organizations, patient leaders and other representatives, including caregivers; and, most important, transactional activities become collaborative, mission-driven initiatives.

The costs of remaining stuck at the “performative plateau,” as we call it, are rising. Patients now arrive at the table far more informed, with lived expertise and concrete proposals for change. They expect their input to shape protocols and support services, not to disappear into a slide deck or marketing narratives. Companies that keep cycling through advisory boards and awareness campaigns — measuring success mainly by activity volume and impressions — are increasingly seen as out of step with the people they claim to serve.

It’s imperative that companies move to the next phase on the maturity curve, which we refer to as the “integrated incline.” When companies make this leap, patient insights become a strategic asset. Biopharma and medical technology companies can use the insights from lived experience to alter clinical trial protocols and rework service models. They can measure success by impact or by how many specific problems they solved. Instead of one‑off gestures that build empathy, there is a repeatable mechanism for translating what patients say into what the organization does.

What our years of experience working with biopharma companies and patient organizations have shown is that progress with patient engagement depends on focus, not on scale. We have seen small, targeted initiatives — such as a project that looked at the impact of the lack of noninvasive diagnostics on access to treatment — deliver more value to patients than a long list of galas and other events that delight the marketing team.

These efforts start with a clearly defined, patient‑identified problem and are designed to remove barriers such as missing Current Procedural Terminology codes, lack of clinical trial participation, outdated guidelines and practical challenges in accessing treatment. By contrast, many large, resource‑intensive programs remain vague about what exactly will change as a result of patient input, making it almost impossible to demonstrate impact.

Why do so many organizations get stuck at the performative phase? Perhaps the most obvious reason is the industry’s tendency to use legal and compliance concerns as an excuse to focus on providers as proxies for patient experience. There is no substitute for working with patients directly. A second reason is a fixation on surface-level metrics: the number of advisory boards convened, events sponsored and social media impressions generated. These easy-to-count metrics reinforce a mindset that more activity equals more maturity. A third is the fragility of many patient affairs programs. Leadership changes can upend strong, relationship‑based programs overnight. The result is a stop‑and‑start pattern marked by bursts of engagement energy followed by organizational amnesia, with patients asked to “reeducate” each new leadership regime.

To get unstuck, organizations need to redefine what good looks like. We encourage leaders to ask: Which decisions changed because of what we heard? What features or product characteristics were informed by patient input? Which protocols, materials or processes are different today as a direct result of patient insight? How are our patient support programs supporting people in ways that reflect real-world realities? Building dashboards that track robust changes — like materials moving through institutional review boards more quickly, positive regulatory and health technology assessment decisions or increased diversity in clinical trials — makes it easier to defend and sustain patient engagement efforts.

Second, companies must capture patient voices and convert them into meaningful actions and operational processes. For example, applying structured patient input to select end points or refine inclusion criteria. This is the essence of operationalizing patient insights.

Third, organizations need to respect the increasing sophistication of patient advocates. On the integrated incline in our maturity curve, engagements are framed as joint problem‑solving exercises: What barriers are you seeing? Which of these can we realistically address? How will we know if we did it successfully? This improves the relevance of the work and helps build durable trust, because patients can see where their input shaped outcomes.

Finally, corporate governance and culture must support continuity. We emphasize the need to institutionalize expectations around patient engagement — through charters, standard operating procedures and performance measures that outlast individuals. When a new leader arrives, they step into a system where patient voices are already baked into all functions and every stage of development and commercialization.

The journey from performative plateau to integrated incline — and eventually on to “partnered pinnacle” — cannot happen overnight, but the urgency is real. Patients and advocates are signaling that tokenism is no longer acceptable. For biopharma and medical technology companies, that expectation is both a challenge and an opportunity. Those willing to treat patients as a source of operational innovation stand to gain trust and legitimacy, competitive advantage and, most importantly, a sharper understanding of the very problems they exist to solve.

Noël Theodosiou is principal and CEO of Luminous; Donna R. Cryer, J.D., is co-founder of CryerHealth; and Amy Dorgan is a health care strategist